Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.08) by 102.53 percent. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $87.309 million which beat the analyst consensus estimate of $77.803 million by 12.22 percent. This is a 69.10 percent increase over sales of $51.632 million the same period last year.